MedTrace Logo

Perioperative Dexmedetomidine and 30-Day Outcomes After Adult Cardiac Surgery

NCT07249164 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 408153

Last updated 2025-11-25

No results posted yet for this study

Summary

This observational study uses de-identified electronic health record data from the TriNetX Global Collaborative Network (2010-01-01 to 2025-07-01) to examine whether perioperative dexmedetomidine (DEX) is associated with 30-day outcomes after adult cardiac surgery. Adults aged 18-100 years undergoing first-time coronary artery bypass grafting or heart valve surgery are included. Exposure is any DEX administration from 24 hours before to 48 hours after the index operation; comparators receive no DEX in this window. The primary outcome is delirium within 30 days. Secondary outcomes are 30-day all-cause mortality, acute kidney injury, pneumonia, sepsis, red blood cell transfusion/major bleeding, myocardial infarction, ischemic stroke/transient ischemic attack, atrial fibrillation, mechanical ventilation \>96 hours (days 4-30), and 30-day readmission (days 1-30). No treatments are assigned by investigators and no identifiable information is used. Findings aim to inform perioperative sedation strategies in routine cardiac surgery care.

Conditions

  • Postoperative Complications
  • Delirium - Postoperative
  • Cardiac Surgical Procedures
  • Coronary Artery Bypass Graft (CABG)
  • Valve Surgery

Interventions

DRUG

Dexmedetomidine

Exposure in routine care within -24 to +48 hours of the index cardiac surgery; dose and regimen not protocol-assigned; observational only; exposure captured from medication records and used to define the dexmedetomidine cohort.

OTHER

Usual care without perioperative dexmedetomidine

No dexmedetomidine administered within -24 to +48 hours of the index surgery; all other management per routine care; observational comparator; dexmedetomidine use outside this window permitted.

Sponsors & Collaborators

  • China Medical University Hospital

    lead OTHER

Principal Investigators

  • En-Bo Wu, MD · Department of Anesthesiology, China Medical University Hospital, Taichung City, Taiwan

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-01
Primary Completion
2025-07-31
Completion
2025-07-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07249164 on ClinicalTrials.gov